Monthly Archives: December 2015

Taking A Look At Barron’s 10 Favorite Stocks For 2016

Though we’re on opposite sides of the Kinder Morgan (KMI) tug of war, I find that the editors of Barron’s and myself tend to sing from the same songbook. We both tend to be contrarian value investors who ignore hype—often to our own detriment. Had I bought the hype and piled into bubbly momentum names like Facebook (FB), Amazon (AMZN) and Netflix (NFLX) this year, I’d be a…

Gilead – Trouble Down On The Pharm?

I have been a rabid Gilead GILD bull for some time now, but when the facts change so does my thesis. My previous article stated that the Wyden-Grassley report could punish Gilead; it apparently got longs’ dander up. Seeking Alpha author Brad Kenagy also took issue with my sell thesis. Below is my response to…

The Fallacy That Weakening Your Currency Generates Prosperity

Of the many economic policies that are accepted as true yet are absolute nonsense, perhaps none is more achingly nonsensical than the notion that weakening a nation’s currency will magically make that nation prosperous. Like the equally nonsensical Keynesian Cargo Cult’s misplaced obsession with “aggregate demand” driving “growth,” the idea that devaluing one’s money makes…

Another Fine Mess

We would be remiss not to mention Pearl Harbor, “A day that will live in infamy”.  Both seem appropriate, one for humor, and the other great sadness. The bottom line—volatility is making a hash of portfolios. Is this a fine mess to launch for the seasonal Santa Claus Rally? So far it’s just a lump…

E

Today Bluebird Bio (BLUE) tanked 37% after reporting trial data that left many analysts and investors mixed on sentiment. The new trial data was presented at the American Society of Hematology — ASH. In this ASH conference many biotech companies come together to present potentially promising data from trials for blood diseases.  The trial data…